Recombinant protein expression for therapeutic applications.
about
Metabolic engineering of a reduced-genome strain of Escherichia coli for L-threonine productionShear-stress-mediated refolding of proteins from aggregates and inclusion bodiesUse of endogenous signal sequences for transient production and efficient secretion by moss (Physcomitrella patens) cells.Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells.A transient tobacco expression system coupled to MALDI-TOF-MS allows validation of the impact of differential targeting on structure and activity of a recombinant therapeutic glycoprotein produced in plants.Eukaryotic protein production in designed storage organellesGlycosylation of therapeutic proteins: an effective strategy to optimize efficacyCharacterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.BAC TG-EMBED: one-step method for high-level, copy-number-dependent, position-independent transgene expression.Chaperone-mediated folding and maturation of the penicillin acylase precursor in the cytoplasm of Escherichia coli.Data fusion-based assessment of raw materials in mammalian cell culture.Characterization and optimization of ArtinM lectin expression in Escherichia coliProduction of therapeutic antibodies in plants.Transgenic plants in the biopharmaceutical market.Application of a reversible immortalization system for the generation of proliferation-controlled cell lines.Current and emerging therapies for the lysosomal storage disorders.Efficient production of L-ribose with a recombinant Escherichia coli biocatalyst.Novel approaches for treating musculoskeletal diseases: molecular orthopedics and systems medicine.Effects of glycosylation on the stability of protein pharmaceuticals.High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Expression of a Human Prostatic Acid Phosphatase (PAP)-IgM Fc Fusion Protein in Plants Using In vitro Tissue Subculture.Recombinant organisms for production of industrial products.Critical Factors Affecting the Success of Cloning, Expression, and Mass Production of Enzymes by Recombinant E. coli.A semi-empirical glycosylation model of a camelid monoclonal antibody under hypothermia cell culture conditions.A novel method to recover inclusion body protein from recombinant E. coli fed-batch processes based on phage ΦX174-derived lysis protein E.Characterization of mammalian cell culture raw materials by combining spectroscopy and chemometrics.A high cell density transient transfection system for therapeutic protein expression based on a CHO GS-knockout cell line: process development and product quality assessment.MAC-T cells as a tool to evaluate lentiviral vector construction targeting recombinant protein expression in milk.Plantibodies in human and animal health: a review.Complete knockout of the lactate dehydrogenase A gene is lethal in pyruvate dehydrogenase kinase 1, 2, 3 down-regulated CHO cells.PhiC31 integrase-mediated genomic integration and stable gene expression in the mouse mammary gland after gene electrotransfer.Free light chain content in culture media reflects recombinant monoclonal antibody productivity and quality.Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners.Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.DUF538 protein super family is predicted to be the potential homologue of bactericidal/permeability-increasing protein in plant system.Combinatorial engineering of ldh-a and bcl-2 for reducing lactate production and improving cell growth in dihydrofolate reductase-deficient Chinese hamster ovary cells.The recombinant chimeric antibody chHAb18 against hepatocellular carcinoma can be produced in milk of transgenic mice.Generation of site-specific retargeting platform cell lines for drug discovery using phiC31 and R4 integrases.
P2860
Q21246022-32E99FAD-17F8-4D1A-A151-0898A698300DQ21559300-56D2D502-4198-41F1-91AF-2659BE9A5F78Q24811666-DE0CAD4A-8666-4D66-83A9-8A2569874E0BQ30479487-42BCF983-C119-4AD3-A65B-A7FB8C14EA49Q33193658-3241CC82-176B-4929-8C46-0E4F7D714435Q33403626-F06726E4-4AE1-43F8-85F8-4BF5BBE40DF5Q33586660-EBA8D781-9C63-45CE-868F-FC66CEBB1968Q33883354-AD7D95CD-BFE1-4891-8BA9-251D273383B2Q33922474-9A446555-FAB6-40F2-B04B-9A01076B80D0Q34097904-511B5299-74C5-4D81-8565-988AA1BFB296Q34261209-E12BEDED-10B8-41FA-9DAB-6D03D09E8D49Q34362814-B3C27E38-6F1C-4E61-9FBC-E6FF141DC3D1Q35547282-58B09122-3B69-4D5E-9CC4-0C7EEC846569Q36066053-4CBCD032-51F2-47EC-AAE6-43BFFF029C46Q36255055-7F1F704E-F3DB-4978-AA39-DA82B9BEBF83Q36302871-5F2074F6-74C7-44D6-B0F1-B789FB1053A7Q36672677-185E7828-77D7-4CB0-9182-AC5909545FA5Q36876937-73ECCFDA-5048-4CD7-A328-0E4AF68194C3Q37114305-229A8BEC-A4CC-43AF-8AAF-9E366073F94DQ37283860-E0684F16-98E1-42D7-81A3-476627CD801CQ37323542-311FBB34-922F-4EE3-ABFF-6FA4672330E8Q37666618-85D9205E-6E8D-4108-AD62-2B7FAA9835E9Q37670494-F64CE787-D380-47D0-B940-621A4E670211Q37843625-98819281-7565-4941-81ED-5D15A9A5CD4AQ38477094-0109DF0E-6DBB-4FA0-8178-2BDA2E4F1012Q38712568-AA7869B2-630C-435A-A581-08E8993A8A5EQ38827509-3568796D-0E6F-473F-8F19-EEC78464FB89Q38844964-B59B815F-DBA0-471B-AC5F-CBDF0F97C986Q38929054-91D0479E-35FA-4662-83AB-51C79C70F1CBQ38941837-8A4F02A6-EC8B-472B-B11C-5FC0F1C478DDQ38949097-6BE175EE-F7D4-4A3D-8271-F76809BFCAA3Q38993696-55439DDC-B259-466C-8498-790F23D627C7Q39052129-47A42FB0-4C5A-44B5-8AEB-276B0AA2B65BQ39135479-4708400C-9B14-41C7-A2EB-F86862D6DD57Q39146031-29830DE7-0C9F-4BF3-9060-47C375A27A47Q39446212-95CFBA95-4295-4A17-BCB2-F834EB3777C1Q39458333-053368F9-519D-4BD7-BF25-0869FD3C87E6Q39500357-F91B947C-181A-4BC1-9C04-4E4E66BCD106Q39692952-738E45F8-9F50-4179-B070-6DF58C076C61Q39788824-9AC15549-A705-4A2C-9C48-7BA0053C1054
P2860
Recombinant protein expression for therapeutic applications.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Recombinant protein expression for therapeutic applications.
@ast
Recombinant protein expression for therapeutic applications.
@en
Recombinant protein expression for therapeutic applications.
@nl
type
label
Recombinant protein expression for therapeutic applications.
@ast
Recombinant protein expression for therapeutic applications.
@en
Recombinant protein expression for therapeutic applications.
@nl
prefLabel
Recombinant protein expression for therapeutic applications.
@ast
Recombinant protein expression for therapeutic applications.
@en
Recombinant protein expression for therapeutic applications.
@nl
P1476
Recombinant protein expression for therapeutic applications.
@en
P2093
Dana C Andersen
Lynne Krummen
P304
P356
10.1016/S0958-1669(02)00300-2
P577
2002-04-01T00:00:00Z